Treatment of Mycobacterium avium Complex (MAC) Pulmonary Disease

2004 ◽  
Vol 57 (3) ◽  
pp. 234 ◽  
Author(s):  
Won Jung Koh ◽  
O Jung Kwon ◽  
Eun Hae Kang ◽  
Gee Young Suh ◽  
Man Pyo Chung ◽  
...  
Keyword(s):  
Pulmonary Disease ◽  
Mycobacterium Avium ◽  
Mycobacterium Avium Complex

The Expanding Spectrum of Mycobacterium avium Complex-Associated Pulmonary Disease

CHEST Journal ◽  
2006 ◽  
Vol 130 (4) ◽  
pp. 1234-1241 ◽  
Author(s):  
E. Andrew Waller ◽  
Archana Roy ◽  
Lisa Brumble ◽  
Andras Khoor ◽  
Margaret M. Johnson ◽  
...  
Keyword(s):  
Pulmonary Disease ◽  
Mycobacterium Avium ◽  
Mycobacterium Avium Complex

hsa-miR-346 is a potential serum biomarker of Mycobacterium avium complex pulmonary disease activity

2017 ◽  
Vol 23 (10) ◽  
pp. 703-708 ◽  
Author(s):  
Tomoyasu Nishimura ◽  
Eiko Tamizu ◽  
Shunsuke Uno ◽  
Yoshifumi Uwamino ◽  
Hiroshi Fujiwara ◽  
...  
Keyword(s):  
Disease Activity ◽  
Pulmonary Disease ◽  
Mycobacterium Avium ◽  
Mycobacterium Avium Complex ◽  
Serum Biomarker

scholarly journals Effective treatment with macrolide and ethambutol for mycobacterium avium complex pulmonary disease

2020 ◽  
Vol 5 ◽  
pp. 34-34
Author(s):  
Masashi Ito ◽  
Yasuhiko Koga ◽  
Noriaki Sunaga ◽  
Toshitaka Maeno
Keyword(s):  
Effective Treatment ◽  
Pulmonary Disease ◽  
Mycobacterium Avium ◽  
Mycobacterium Avium Complex

scholarly journals Long-Term Treatment Outcome of Progressive Mycobacterium avium Complex Pulmonary Disease

2020 ◽  
Vol 9 (5) ◽  
pp. 1315 ◽  
Author(s):  
Kiyoharu Fukushima ◽  
Seigo Kitada ◽  
Yuko Abe ◽  
Yuji Yamamoto ◽  
Takanori Matsuki ◽  
...  
Keyword(s):  
Pulmonary Disease ◽  
Mycobacterium Avium ◽  
Mycobacterium Avium Complex ◽  
Refractory Disease ◽  
Multidrug Therapy ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Long Term Treatment ◽  
Standardized Treatment

Background: Multidrug therapy is essential for preventing respiratory failure in patients with highly progressive Mycobacterium avium complex pulmonary disease (MAC-PD). However, the prognosis and long-term outcome following combination therapy is poorly understood. Methods: We retrospectively evaluated the clinical characteristics and long-term outcomes in patients with chemo-naïve progressive MAC-PD, hospitalized for first-line multidrug therapy. Results: Among 125 patients, 86 (68.8%) received standardized treatment (rifampicin, ethambutol, clarithromycin), 25 (20.0%) received a fluoroquinolone (FQ)-containing regimen, and 53 (42.4%) received aminoglycoside injection. The sputum conversion rate was 80.0%, and was independently associated with standardized treatment. The incidence of refractory disease (45.6%) was independently and negatively associated with standardized regimen and aminoglycoside use. Choice of an FQ-containing regimen was not associated with positive outcome. Clarithromycin resistance occurred in 16.8% and was independently associated with refractory disease. MAC-PD-associated death occurred in 3.3% of patients with non-cavitary nodular bronchiectasis (NB) and 21.3% with cavitary MAC-PD over a median follow-up period of 56.4 months. The rates of MAC-PD-associated death were comparable between cavitary-NB and fibrocavitary disease. Concurrent chronic pulmonary aspergillosis (CPA) occurred in 13 (17.3%) patients with cavitary MAC-PD, and age, diabetes mellitus, and CPA were independent risk factors for mortality. Conclusions: Standardized intensive multidrug treatment reduces disease progression and persistence in progressive MAC-PD. Cavitary NB may differ from, rather than being just an advanced stage of, non-cavitary NB. The high incidence and significant mortality of CPA in cavitary MAC-PD highlight the need for early diagnosis and treatment.

Sign in / Sign up

Export Citation Format

Share Document